According to Eric W

The new method uses genetic pathways in small small to manipulate to manipulate in order to invent new potential drugs. The ability to make these chemicals in the laboratory opens up endless possibilities for the development of medicines for cancer, HIV too too, according to Eric W. Schmidt, bacteria . Of Medicinal Chemistry at the University of Utah College of Pharmacy and lead author of of the study. – ‘This is a new way to attack the problem,’Schmidt said. ‘We hope we can use this to find a way to natural molecules of compounds through single mutations in the DNA. ‘.

###Contact: Eric W. Schmidt,For the study gained Schmidt sample bacteria from 46 squirts in the tropical Pacific near New Guinea.staff are members of the study: Margo G. Haywood from the Oregon Health Sciences University, Sebastian Sudek, from the Scripps Institution of Oceanography at the University of California, San Diego; Rosovitz MJ and Jacques Ravel, both of The Institute for Genomic Research in Rockville, Maryland, Mohamed S. Donia and Brian J. Hathaway, both. Of the Department of Medical Chemistry, University of Utah College of Pharmacy.

VivaGel is a vaginal microbicide moment in clinical development to the preventing the transmission of HIV and genital herpes . This HPV Assay within the framework of within the framework of Star Pharmashare strategy of to explore living! Potential of VivaGel into other sexually transmissible infections.

About Starpharma Holdings LtdStarpharma Holdings Limited ! has a world leader in in the development of of dendrimer nanotechnologies for pharmaceutical, life-science and other applications. Level SPL consisting principally two operating two operating societies Starpharma is Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc. In Michigan, USA. , have balanced by level SPL dendrimer technology. Already commercially in terms of diagnostic elements or laboratory reagents.